Table 1 Main bisphosphonates used in pediatric age (adapted from Baroncelli G.I. et al.) [90]
From: Growth and puberty in children with juvenile idiopathic arthritis
Name | Oral | Parenteral | Dose | Relative potency |
|---|---|---|---|---|
Etidronate | + | + | p.o.:5–40 mg/kg per day iv: 400 mg per day per 2 weeks, every 3 months | 1 |
Clodronate | + | + | p.o.: 200 mg per day /subdivided into 3 doses iv: (dilute in 200–250 ml NSS, in 2–3 h) 2 mg/kg per day every 3–6 months | 10 |
Pamidronate |  | + | (dilute in 100–250 ml of NSS, in 3–4 h)0.5–1.5 mg/kg per day for 3 days; every 2–6 months) | 100 |
Neridronate |  | + | (dilute in 200–250 ml NSS, in 3 h)1–2 mg/kg per every 3–6 months | 100 |
Zoledronate |  | + | (dilute in 50 ml NSS, in 30–45 min) 0.015–0.05 mg/kg every 3–6 months | > 10,000 |
Aledronate | + |  | 1–2 mg/kg/week <  40 kg: 5 mg/day or 35 mg/week >  40 kg: 10 mg/day or 70 mg/week Maximum dose: 70 mg/week | 100–1000 |
Risedronate | + |  | 15 mg per week (< 40 kg) 30 mg per week (> 40 kg) Maximum dose: 30 mg/week | 1000–10,000 |